Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718217 | 0.92 | CTSS (0.80) | CTSSCD74 | |
| SCHEMBL5532050 | 0.89 | CTSS (1.00) | CTSSCD74 | |
| SCHEMBL5787751 | 0.88 | CTSS (0.65) | CTSSCD74 | |
| SCHEMBL1988915 | 0.86 | CTSS (1.00) | CTSSCD74 | |
| SCHEMBL5532235 | 0.82 | CTSS (1.00) | CTSSCD74 | |
| SCHEMBL5528511 | 0.82 | CTSS (0.90) | CTSSCD74 | |
| SCHEMBL5533892 | 0.82 | CTSS (1.00) | CTSSCD74 | |
| SCHEMBL5534975 | 0.81 | CTSS (1.00) | CTSSCD74 | |
| SCHEMBL4715556 | 0.81 | CTSS (1.00) | CTSSCD74 | |
| SCHEMBL5528100 | 0.81 | CTSS (1.00) | CTSSCD74 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309593-B1 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARM INC (US) | 2006-03-15 | — | — | EP | claimed |
| US-20170333368-A1 | Paediatric Compositions For Treating Multiple Sclerosis | NOVARTIS AG (CH) | 2017-11-23 | — | — | US | disclosed |
| US-20170128389-A1 | Paediatric Compositions For Treating Multiple Sclerosis | NOVARTIS AG (CH) | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333368-A1 | Paediatric Compositions For Treating Multiple Sclerosis | SMN1; SMN2, PMP22, CFTR | CTSS 2266/4885CD74 193/4885 |
| US-20170128389-A1 | Paediatric Compositions For Treating Multiple Sclerosis | SMN1; SMN2, PMP22, CFTR | CTSS 2185/4885CD74 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.